Latest

major depressive disorder

·May 13, 2026·7 min read

Neurofeedback Trains Brain to Stop Depressive Rumination

Researchers are using real-time fMRI neurofeedback to transform brain training into a video game that targets rumination. By teaching patients to regulate the coupling between the brain's self-referential and goal-directed centers, this precision psychiatry approach successfully reduced depressive symptoms. This study marks a major step toward a future where patients receive personalized, portable brain-training headsets to treat their specific mental health needs.

Featured Neuroscience Psychology

·May 11, 2026·8 min read

Decoding the Metabolic Roots of Bipolar Disorder

New research identifies a specific pathway where insulin resistance leads to gray matter loss and cognitive impairment in BD patients, but not those with Major Depression. This discovery opens the door for personalized treatments, such as GLP-1 agonists, to target the metabolic roots of cognitive decline.

Featured Neuroscience Psychology

·April 22, 2026·8 min read

The Cellular Roots of Mental Illness

Researchers developed PhysMAP, an AI tool that identifies specific neuron types in electrical brain recordings to help treat psychiatric "circuitopathies."

Featured Neuroscience Psychology

·March 11, 2026·8 min read

Depression’s “Energy Crisis”: Fatigue Starts at the Cellular Level

New research reveals that depression-related fatigue is caused by cells that overwork at rest but "stall" when life gets stressful.

Featured Neuroscience Psychology

·May 22, 2025·7 min read

Potassium Channel Drug Offers New Hope for Treating Depression

Two new studies reveal that ezogabine, a drug originally approved for epilepsy, may alleviate depression symptoms by targeting potassium channels in the brain. Researchers found that the drug improves function in reward-related brain regions like the ventral tegmental area (VTA), which is key to motivation and pleasure.

Featured Neuroscience Psychology

·November 13, 2024·4 min read

Psychedelic Therapy Could Benefit 5.6 Million People with Depression

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment-resistant depression, offering a powerful alternative to traditional treatments. Researchers applied medical criteria to a national pool of patients and found that over half might be eligible for psilocybin therapy, pending FDA approval. If approved, this therapy could significantly impact public health policies, insurance frameworks, and economic costs by reducing reliance on long-term antidepressant prescriptions.

Featured Neuroscience Psychology

·July 5, 2023·5 min read

Abnormal Brain Folding a Biomarker for Major Depressive Disorder

Researchers discovered a biomarker for major depressive disorder (MDD) in the brain's outer layer folds, or gyri. The investigation, first of its kind, associates MDD with the local gyrification index (LGI), a measure of cortical folding derived from brain scans.

Featured Neuroscience Psychology

·June 27, 2023·5 min read

Brain Imaging Unveils Multiple Subtypes of Major Depressive Disorder

A recent study identified multiple subtypes of Major Depressive Disorder (MDD) using brain imaging. Over 2,000 participants were involved in the study, which analyzed functional connectivity in the brain.

Featured Neuroscience Psychology

·June 19, 2023·6 min read

Thyroid Hormones and Blood Sugar Linked to Major Depressive Disorder Severity

A new study provides crucial insights into the potential relationship between thyroid hormones, blood sugar, lipid levels, and their effects on Major Depressive Disorder (MDD). Researchers explored the intricate roles of these biological markers on MDD prognosis, the probability of suicidal behavior, and potential treatments.

Featured Neuroscience Psychology

·March 30, 2023·5 min read

Newly Discovered Trigger for Major Depression Opens New Possibilities for Treatments

Glycine, a common amino acid, appears to play a role in the development of major depression, anxiety, and other mood-related disorders.

Featured Genetics Neuroscience Psychology

·March 24, 2023·5 min read

New Discovery Reveals Sex-Specific Causes of Depression Triggered by Stress Hormones Dysfunction

Men are more likely to have a dysregulated HPA axis that is associated with depressive symptoms, while women have higher levels of binding proteins for stress hormones that may prevent dysregulation of the HPA axis. The findings shed new light on how stress hormones impact dopamine transmission and how this impacts depression on a sex-specific basis.